|
|
Article: FDA approves new fibromyalgia therapy.(NEWS)
- Article from:
- OB GYN News
- Article date:
- March 1, 2009
- Author:
CopyrightCOPYRIGHT 2009 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Milnacipran, a norepinephrine-serotonin reuptake inhibitor, has been approved by the Food and Drug Administration for the management of fibromyalgia in adults, the third drug approved for this indication.
Approval was based on the results of two phase III studies of a total of 2,084 patients with fibromyalgia, which found that during 3-6 months of treatment, those (1,460 patients) treated with 100 mg or 200 mg of milnacipran per day experienced statistically significant and clinically meaningful improvements in pain, patient global assessment, and physical function, compared with those on placebo.
Milnacipran is a dual reuptake inhibitor that ...
Related newspaper, magazine, and journal articles:
|
|
Article: Forest Laboratories, Inc. and Cypress Bioscience, ...
PR Newswire;
January 5, 2006 ;
700+ words
... ... FirstCall/ -- Forest Laboratories, Inc. and Cypress ... study evaluating milnacipran as a treatment ... development of milnacipran. Actual results ... development of milnacipran. About Forest Laboratories, Inc. Forest ...
|
|